公开(公告)号：US20230312723A1

公开(公告)日：2023-10-05

申请号：US18050236

申请日：2022-10-27

Applicant: Genentech, Inc.

Inventor： Mark Lawrence MCCLELAND ,  Simonetta MOCCI ,  Wei ZOU ,  Yu DENG ,  Hiroshi KURIKI

IPC: C07K16/28 ,  C12Q1/6886 ,  G01N33/574 ,  A61K31/519 ,  A61K33/243 ,  A61K31/282 ,  A61P35/00

CPC classification number: C07K16/2827 ,  C12Q1/6886 ,  G01N33/57492 ,  A61K31/519 ,  A61K33/243 ,  A61K31/282 ,  A61P35/00 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N2333/70596 ,  C07K2317/24

Abstract: The disclosure provides methods and compositions for treating non-small cell lung cancer (NSCLC; e.g., squamous or non-squamous NSCLC, including stage IV NSCLC) in a subject, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) in combination with a platinum-based chemotherapy (e.g., cisplatin or carboplatin and gemcitabine) to the subject. Exemplary subjects that may be treated using the compositions and methods of the disclosure include those that exhibits a heightened blood tumor mutational burden (bTMB) score relative to a reference bTMB score. Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab) and/or a platinum-based chemotherapy (e.g., cisplatin or carboplatin and gemcitabine), pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in treating NSCLC (e.g., squamous or non-squamous NSCLC, including stage IV NSCLC) in a subject, such as a subject having an elevated bTMB score prior to the onset of treatment.